Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission

Clinical Lymphoma and Myeloma

Volumn 7, Issue 6, 2007, Pages 400-405

  Rueda, Antonio ^a   Olmos, David ^a,c   Villareal, Vicente ^b   Torres, Esperanza ^a   Pajares, Bella Isabel ^a   Alba, Emilio ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Hospital Punta Europa   (Spain)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cytokines; Performance status; Prognostic factors

Indexed keywords

CYTOKINE; VASCULOTROPIN;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; BONE MARROW; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; SYMPTOMATOLOGY;

EID: 34447300966     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.018     Document Type: Article

References (32)

1. Cartwright R, Brincker H, Carli PM, et al. The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer 1999; 35:627-633.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
3. Kandin ME, Liebowitz DN. Cytokines and cytokine receptors in Hodgkin's disease. In: Mauch PM, Armitage JO, Hoppe RT, eds. Hodgkin's Disease. 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:139-158.
4. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma - diagnosis and treatment. Lancet Oncol 2004; 5:19-26.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
6. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-61.
7. Takahashi Y, Bucana CD, Liu W, et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88:1146-1151.
8. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005; 105:1383-1395.
9. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027.
10. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
11. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999; 94:3717-3721.
12. Molica S, Vitelli G, Levato D, et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107:605-610.
13. Di Raimondo F, Azzaro MP, Palumbo G, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000; 85:800-805.
14. Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000; 96:768-770.
15. Musolino C, Calabro L, Bellomo G, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002; 69:159-163.
16. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90:3167-3172.
17. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol 2002; 197:677-683.
18. Agarwal B, Naresh KN. Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol 2003; 201:334-335.
19. Mainou-Fowler T, Angus B, Miller S, et al. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 2006; 47:223-230.
20. Giles FJ, Vose JM, Do KA, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004; 28:595-604.
21. Passam FH, Alexandrakis MG, Moschandrea J, et al. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. Int J Immunopathol Pharmacol 2006; 19:161-170.
22. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
23. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26:1063-1083.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
25. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 1998; 339:1506-1514.
26. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258-2272.
27. Rosenberg SA, Boiron M, DeVita VT Jr, et al. Report of the committee on Hodgkin's disease staging procedures. Cancer Res 1971; 31:1862-1863.
28. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-259.
29. Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48:1521-1529.
30. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol 2001; 67:279-288.
31. Specht L. Tumour burden as the main indicator of prognosis in Hodgkin's disease. Eur J Cancer 1992; 28A:1982-1985.
32. Gobbi PG, Broglia C, Di Giulio G, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 2004; 101:1824-1834.